MedTrace Logo

Prevention of Early Postmenopausal Bone Loss With Lactobacillus Reuteri

NCT04169789 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 239

Last updated 2023-02-06

No results posted yet for this study

Summary

This study evaluates the effect of two different doses of Lactobacillus reuteri ATCC PTA 6475 (L.reuteri 6475) on bone loss in early postmenopausal women. One third of the participants will be randomised to the lower dose, one third to the higher dose and one third to placebo.

Conditions

  • Postmenopausal Osteoporosis

Interventions

DIETARY_SUPPLEMENT

Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)

L.reuteri high or low dose with cholecalciferol compared to cholecalciferol only.

Sponsors & Collaborators

  • BioGaia AB

    collaborator INDUSTRY

  • Sahlgrenska University Hospital

    lead OTHER

Principal Investigators

  • Mattias Lorentzon, MD, PhD · Sahlgrenska University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-04
Primary Completion
2022-10-18
Completion
2022-10-18

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04169789 on ClinicalTrials.gov